Table 1 Clinical characteristics of the COVID-19 patients included. We have included the worst PF and highest PEEP. Results of continuous variables are expressed as mean and standard deviation or median and interquartile range as appropriate. Categorical variables are expressed as frequency (percentage). SOFA sequential organ failure assessment, APACHE II Acute Physiology and Chronic Health disease Classification System II, ICU intensive care unit, PF PaO2/FiO2 ratio, PEEP positive end-expiratory pressure, AKI acute kidney injury, CRRT continuous renal replacement therapy, LMWH low-molecular-weight heparin
From: Vitamin C levels in patients with SARS-CoV-2-associated acute respiratory distress syndrome
Clinical characteristics | COVID-19 ARDS (n = 18) |
|---|---|
Age (mean, standard deviation, years) | 59 ± 9 |
Male (n, %) | 7 (38) |
SOFA score (median, interquartile range, points) | 4 (1) |
APACHE II score (mean, standard deviation, points) | 16.2 ± 1.6 |
Interval between ICU admission and blood samples extraction for vitamin C measurement (mean, standard deviation, days) | 17.5 ± 1.7 |
Interval between intubation and blood samples extraction for vitamin C measurement (mean, standard deviation, days) | 17.5 ± 1.7 |
ARDS-related variables | |
PaO2/FIO2 at the time of vitamin C measurement (mean, standard deviation, mmHg) | 94.4 ± 5.9 |
PEEP (cmH2O) at the time of vitamin C measurement (median, interquartile range, points) | 13.6 (3) |
Neuromuscular blockade during ICU admission (n, %) | 18 (100) |
Prone position during ICU admission (n, %) | 17 (94) |
Renal failure | |
AKI (n, %) | 3/18 (16) |
AKI I (n, %) | 2/3 (66) |
AKI III (n, %) | 1/3 (33) |
CRRT (n, %) | 1/18 (6) |
COVID-19-related therapies | |
Antivirals (n, %) | 14 (77) |
Hydroxychloroquine (n, %) | 17 (94) |
Tocilizumab (n, %) | 13 (72) |
Methylprednisolone (n, %) | 10 (55) |
LMWH anticoagulant (n, %) | 8 (44) |
Outcomes | |
Length of ICU stay (mean, standard deviation, days) | 28.4 ± 3.4 |
Number of hospital survivors (n, %) | 18 (100) |